Sonoma Biotherapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Sonoma Biotherapeutics's estimated annual revenue is currently $30.4M per year.
- Sonoma Biotherapeutics's estimated revenue per employee is $193,750
- Sonoma Biotherapeutics's total funding is $335M.
Employee Data
- Sonoma Biotherapeutics has 157 Employees.
- Sonoma Biotherapeutics grew their employee count by -5% last year.
Sonoma Biotherapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO and Co-Founder | Reveal Email/Phone |
2 | VP | Reveal Email/Phone |
3 | CEO, President | Reveal Email/Phone |
4 | VP Clinical Operations | Reveal Email/Phone |
5 | VP, Translational Sciences | Reveal Email/Phone |
6 | VP Data Science | Reveal Email/Phone |
7 | VP, Process and Analytical Development | Reveal Email/Phone |
8 | VP Discovery Sciences | Reveal Email/Phone |
9 | VP, Head Quality | Reveal Email/Phone |
10 | VP Regulatory | Reveal Email/Phone |
Sonoma Biotherapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Sonoma Biotherapeutics?
Sonoma Biotherapeutics is inventing the future of living therapies for autoimmune disease — safe, effective treatments as unique as each individual patient. Regulatory T cell therapies that harness a patient’s own immune cells, powerful next generation gene editing techniques and advanced manufacturing and quality assurance processes. Sonoma’s mission is to create a best-in-class regulatory T cell therapy that delivers long-lasting, highly efficacious treatments leading to cures across a spectrum of autoimmune and degenerative diseases.
keywords:N/A
$335M
Total Funding
157
Number of Employees
$30.4M
Revenue (est)
-5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Sonoma Biotherapeutics News
BiotechVenture CapitalSpecial ReportsElevateBioSonoma BiotherapeuticsEQRxLarondeNeumora TherapeuticsAdagio TherapeuticsAltos LabsInsilico...
... CapitalSpecial ReportsElevateBioSonoma BiotherapeuticsEQRxLarondeNeumora TherapeuticsAdagio TherapeuticsAltos LabsInsilico Medicine.
Arrowhead and Vivo Capital are forming a new company called Visirna Therapeutics to take four of the biotech's RNAi therapies to China,...
Sonoma Biotherapeutics, an immune tolerance company focused on the development of regulatory T cell (Treg) therapies, has announced an oversubscribed $265 million Series B financing. Proceeds from the financing will be used to advance Sonoma Bio’s Treg cell therapy platform and a novel Teff cond ...
Sonoma Biotherapeutics’ platform and product candidates aim to restore immune system balance through complementary regulatory T cell (Treg) therapy and effector T cell (Teff) conditioning Series B financing comprised of strong syndicate of leading life science investors Financing supports the ...
Other Companies in San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $24.2M | 157 | -12% | N/A |
#2 | $7.5M | 157 | 22% | N/A |
#3 | $46.6M | 157 | 8% | N/A |
#4 | $36.3M | 157 | 8% | N/A |
#5 | $22.1M | 158 | 4% | $40M |